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Abstract
Background: To identify patients with chronic obstructive pulmonary disease (COPD) who are susceptible to frequent
exacerbations is important. Although periodontitis aggravated by poor oral hygiene might increase the risk of lower
respiratory tract infection, the relationship between periodontitis and COPD exacerbations remains unknown. This
prospective cohort study investigates the relationship between periodontitis-related antibody and exacerbation frequency
over a one-year period.
Methods: We assessed an IgG antibody titer against Porphyromonas gingivalis, which is a major pathogen of periodontitis,
and then prospectively followed up 93 individuals over one year to detect exacerbations.
Results: The numbers of exacerbations and the rate of individuals with frequent exacerbations (at least two per year) were
significantly lower in patients with higher IgG titer than those with normal IgG titer (0.8 vs. 1.2 per year, p = 0.045 and 14.3
vs. 38.6%, p = 0.009, respectively). Multivariate logistic regression analysis showed that being normal-IgG titer for
periodontitis-related antibody significantly increased the risk of frequent exacerbations (relative risk, 5.27, 95% confidence
interval, 1.30–25.7; p = 0.019) after adjusting for other possible confounders, such as a history of exacerbations in the past
year, disease severity, COPD medication and smoking status.
Conclusions: Normal-IgG titer for periodontitis-related antibody can be an independent predictor of frequent
exacerbations. Measuring periodontitis-related antibody titers might be useful to identify patients with susceptibility to
frequent exacerbations so that an aggressive prevention strategy can be designed.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth
leading cause of death worldwide, and it is associated with an
increasing economic cost and social burden [1]. The natural
history of COPD is punctuated by exacerbations, which consist of
acute episodes of worsening symptoms that might warrant changes
in regular medications. These exacerbations negatively impact
lung function, health-related quality of life, prognosis and
socioeconomic burden [1]. Thus, exploring predictors of exacer-
bations and identifying patients with susceptibility to frequent
exacerbations are important to design an efficient preventive
strategy.
Factors associated with exacerbation include disease severity
[1], a history of exacerbations [2], smoking [3], chronic
inflammation [4], bacterial colonization [5] and gastro-esophageal
reflux disease [6]. In addition, we have reported an association
between an impaired swallowing reflex and bacterial colonization,
systemic inflammation and an increased risk of exacerbations [7].
Since an impaired swallowing reflex might cause the aspiration of
oral bacteria leading to lower respiratory tract infection, and poor
oral hygiene itself is involved in the risk of aspiration pneumonia
[8–10], we speculated that poor oral hygiene would increase the
frequency of exacerbations.
Periodontitis is a common oral infectious disease that is
associated with poor oral hygiene among the general population.
It is characterized by inflammation of the periodontium induced
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by subgingival plaque bacteria such as anaerobic gram-negative
rods [11], that can also be associated with COPD exacerbation
[12]. Chronic marginal periodontitis is more prevalent among
patients with severe COPD than in other equally severe
respiratory diseases [13] and the prevalence of periodontitis
increases together with COPD severity [14]. In addition, serum
antibody to Porphyromonas gingivalis (P. gingivalis), which is a
frequently isolated pathogen, can be involved in systemic diseases
such as cardiovascular disease [15–17]. However, the relationship
between periodontitis and COPD exacerbation remains unclear.
We postulated that periodontitis is associated with COPD
exacerbations. This prospective cohort study investigated the
impact of baseline antibody titers for periodontal antigen (an index
of periodontitis) on COPD exacerbation frequency for over one
year. We also investigated the relationship between elevated-IgG




The study was approved by the ethics committee of Kyoto
University (approval No. E182), and written informed consent was
obtained from all participants.
Protocol and Study Participants
We recruited 109 patients with COPD from an outpatient clinic
at Kyoto University Hospital, Japan, between September 2006
and August 2008 for this study. All patients provided written
informed consent to participate. Blood and induced sputum
samples were collected under stable conditions (as defined below)
at entry for subsequent assay. We excluded 16 patients based on
the following criteria: female, Brinkman index ,10 pack-years,
respiratory diseases other than COPD, daily intake of systemic
corticosteroids and complicated with malignant diseases within 5
years. Thus, 93 patients were prospectively followed up for over
one year to detect exacerbations.
Exacerbation Criteria
Exacerbations and stable periods were prospectively identified
using diary cards as in our previous study [6,7]. We adopted a
modified version of the East London cohort study criteria to define
COPD exacerbations [6] based on an increase in any two ‘‘major’’
symptoms (dyspnea, sputum purulence and sputum quantity) or an
increase in one ‘‘major’’ and one ‘‘minor’’ symptom (wheeze, sore
throat, cough and nasal congestion/discharge) for at least two
consecutive days [18]. Stable condition was defined as an
exacerbation-free interval of .4 weeks [6].
Clinical Examinations
Pulmonary function tests (Chestac-65V; Chest MI Corp.;
Tokyo, Japan) were performed after inhaling short-acting bron-
chodilators (salbutamol and ipratropium) at entry into the study.
Lung volumes and diffusion capacity were measured using helium
dilation and the single-breath method, respectively. The British
Medical Research Council dyspnea scale (MRC) and Charlson
Commorbidities index were also assessed.
Venous blood at entry was collected on the entry day during the
stable period and stored at –80uC. Serum levels of immunoglob-
ulin G (IgG) against P. gingivalis were measured using an enzyme-
linked immunosorbent assay (ELISA) based on validated method
[15,19,20]. Since the FDC381 and Su63 strains of P. gingivalis are
serologically different, we separately measured antibody titers of
PgFDC381 and PgSu63. We defined the cut-off point as the mean
+2 SD of the controls based on the reported dataset of IgG titers to
PgFDC381 and PgSU63 among 10 control individuals [20]. We
divided COPD patients into two groups: one is patients whose
antibody titers were higher than mean +2SD (High-IgG titer
group), and the other includes those whose titers were lower than
mean +2SD (Normal-IgG titer group).
Serum C-reactive protein (CRP) and c-globulin were measured
using the High Sensitivity CRP assay (Behring Diagnostics,
Westwood, MA, USA), and cellulose acetate electrophoresis,
respectively. We assayed 27 cytokines (PDGF, IL-1b, IL-1Ra, IL-
2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,IL-10, IL-12, IL-13, IL-15, IL-
17, eotaxin, FGF, G-CSF, GM-CSF, IFN-c, IP-10,MCP-1, MIP-
1a, MIP-1b, RANTES, TNF-a and VEGF) in 62 patients using a
multiplex bead-based immunoassay kit (Bioplex, Bio-Rad Labo-
ratories, Life Science Research Group, Hercules, CA, USA).
Statistical Analysis
Data were statistically analyzed using the Mann-Whitney U-test
and the x2 test with JMP 8.0 software (SAS Campus Drive, Cary,
NC, USA) and all results are presented as medians and 25th-75th
percentiles. Independent predictors of frequent exacerbations
(defined as at least two exacerbations per year) were detected
using multivariate logistic regression analysis. All p-values are two-
sided and p,0.05 was considered significant.
Results
Baseline Characteristics of Study Patients
Table 1 shows the baseline characteristics of the 93 patients and
the prevalence of elevated IgG antibody titer against P. gingivalis.
The distribution of standardized IgG values were 1.29
(20.05,3.75) for PgFDC 381 and 0.06 (20.47,0.76) for Pg
SU63. The rates of high IgG titer against PgFDC381 and PgSu63
were 52.7% and 23.7%, respectively. Table 2 shows that age,
smoking status, smoking index, body mass index, forced expiratory
volume in 1 second (FEV1), Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stage, and MRC did not differ
between High-IgG titer group and Normal-IgG titer group.
Comorbidities assessed by Charlson Comrbidity index [21] were
similar between these two groups. The frequency of using inhaled
corticosteroid (ICS) was lower and serum c-globulin levels were
higher in High-IgG titer group than in Normal-IgG titer group,
whereas the frequency of using tiotropium and long-acting b2
agonists (LABA), and of serum levels of CRP did not differ
(Table 3). None of the patients received salmeterol/fluticasone
propionate combination therapy.
Relationship between Elevated IgG Antibody Titer
against P. gingivalis and Exacerbation Frequency
We hypothesized that more periodontitis lead to more
exacerbations, but in contrast to our hypothesis, exacerbations
were less frequent in High-IgG titer group than in Normal-IgG
titer group (0.8 vs. 1.2 per year, p =0.045, Figure 1 and Table 4).
Moreover, the rate of patients who experienced frequent
exacerbations (at least two per year) was also lower in High-IgG
titer group than in Normal-IgG titer group (14.3% vs. 38.6%, p
=0.009, Table 4).
Multivariate Analysis to Detect Independent Predictors of
Frequent Exacerbation
We performed multivariate logistic regression analysis to
determine whether being normal IgG antibody titer against P.
gingivalis could be an independent risk factor for frequent
Periodontitis Antibody and COPD Exacerbation
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exacerbations (Table 5). This analysis included the occurrence of
frequent exacerbations as a dependent categorical variable and
higher IgG antibody titer against P. gingivalis, age, smoking status,
body mass index, c-globulin, CRP, use of ICS, tiotropium and
LABA, FEV1(%predicted) and a history of exacerbations in the
year before entry as independent variables. We found that a
history of exacerbation in the previous year and normal IgG
antibody titer against P. gingivalis significantly increased the
occurrence of exacerbations (Relative Risk [RR] 4.43, 95%
confidence interval [95%CI] 1.20–19.6, p =0.025; RR 5.27,
95%CI 1.30–25.7, p = 0.019, respectively).
Relationships between Elevated IgG Antibody Titer
against P. gingivalis and Serum Inflammatory Cytokines:
Subanalysis of Immune Status among 62 Patients
Tables S1 and S2 show the results of a comparison of 27
cytokines in 62 patients placed in groups that were higher-IgG titer
or normal-IgG titer against P. gingivalis according to the multiplex
bead-based immunoassay. Levels of serum IL-4 and IL-7 were
significantly higher in Normal-IgG titer group than in High-IgG
titer group, whereas the other cytokines did not significantly differ
between them.
Discussion
We demonstrated that the frequency of exacerbations was
higher among patients with COPD whose antibody titer against P.
gingivalis was normal compared with those whose antibody titer
against P. gingivalis was higher. Multivariate logistic regression
analysis showed that being normal-IgG titer against P. gingivalis
was independently associated with frequent exacerbations during
the following year after adjustment for established exacerbation-
related factors such as a history of exacerbation [2], FEV1 [22,23]
and the use of COPD medications [24,25]. These findings
contradicted our hypothesis that periodontitis is a risk factor for
COPD exacerbation. Nevertheless, the present findings are
important because, to our knowledge, this is the first study to
demonstrate a relationship between antibodies and COPD
exacerbation, and to indicate the value of P. gingivalis-related
antibodies as a predictor of exacerbation. There were no
significant differences between High-IgG titer group and Nor-
mal-IgG titer group in age, FEV1, GOLD stage, and exacerbation
frequencies at the baseline characteristics.
It has been shown that a history of COPD exacerbations is a
good predictor for the future exacerbation [2] and our result
suggests that the possible mechanism for the frequent exacerba-
tion, thus it seems apparently inconsistent that the frequencies of
COPD exacerbation in the previous year are similar in the two
groups in the baseline characteristics. However, it is also reported
that considerable part of patients who experienced exacerbation in
the previous year did not experience COPD exacerbation in the
following year [2]. Moreover, we could not specify the timing that
the antibody titers increased or decreased. It is possible that the
severity of periodontitis, antibody titers or immune status might be
different in the previous year and the actual prospective
observational period. Further investigation is needed to verify
these speculations.
Periodontitis is a disease that afflicts dentate people, so we
checked only in cases with teeth. In the dentate patients group,
Table 1. Patients’ baseline characteristics (n = 93).
Age (y) 73 (45–88)
Body mass index (kg/m2) 21.7 (14.3–30.5)
Smoking index (pack-years) 57 (20–220)
FEV1 (% predicted) 55.0 (19.8–107.1)
GOLD stage, I/II/III/IV 12/46/30/5
High-IgG titer, n (%)
PgFDC381 49 (52.7)
PgSu63 22 (23.7)
FEV1, forced expiratory volume in one second;
GOLD, Global Initiative for Chronic Obstructive Lung Disease;
‘‘High-IgG titer’’ includes subjects whose titers against Porphyromonas gingivalis
(PgFDC381 and PgSu63) are above mean+2SD of healthy subsets [20].
Pg, Porphyromonas gingivalis. Data are expressed as median (25th–75th
percentiles).
doi:10.1371/journal.pone.0040570.t001





(n =49) p value
Age (y) 74 (65–78) 73 (66–78) 0.83
Smoking status (Former : Current) 37:7 43:6 0.77
Smoking index (pack-years) 60 (47–102) 53 (40–80) 0.07
Body mass index (kg/m2) 21.3 (19.5–23.3) 22.0 (20.1–23.5) 0.46
FEV1 (% predicted) 54.4 (39.5–66.7) 56.5 (42.4–72.4) 0.39
GOLD stage (I/II/III/IV) 5/23/13/3 7/23/17/2 0.94
Numbers of patients with frequent exacerbations in the
previous year, n (%)
22 (50.0) 24 (49.0) 1.00
MRC 1 (1–2) 1 (1–2) 0.86
Charlson comorbidity index 2 (1–3) 2 (1–3) 0.76
High-IgG titer group includes subjects whose titers against Porphyromonas gingivalis (PgFDC381 and/or PgSu63) are above mean+2SD of healthy subsets [20].
‘‘Frequent exacerbations’’ are defined as $2 exacerbations per year.
FEV1, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.; MRC, British Medical Research Council. Data are expressed
as medians (25th–75th percentiles).
doi:10.1371/journal.pone.0040570.t002
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elevated serum IgG antibody titer didn’t associated with exacer-
bation frequency directly, but frequent exacerbations (at least two
per year) was lower in High-IgG titer group than in Normal-IgG
titer group (15.6% vs. 44.0%, p =0.018, Table S3).
Because periodontitis is often complicated with diabetic mellitus
[26,27] or other systemic diseases [16,17,28–30], we also checked
the comorbidities by using Charlson Comorbidities index. There
was no difference between High-IgG titer group and Normal-IgG
titer group. In this study population, comorbidities of COPD were
not influenced on the periodontitis.
The importance of predictors of exacerbation is becoming
recognized because identifying patients with susceptibility to
frequent exacerbations allows the design of an aggressive
prevention strategy [2]. We previously showed that an impaired
swallowing reflex can predict frequent exacerbations [7].
Assuming that the aspiration of bacteria into the lungs especially
among patients with an impaired swallowing reflex can cause
lower respiratory tract infection, we postulated that the common
oral infection, periodontitis, is associated with exacerbation.
Although a diagnosis of periodontitis requires a systematic
approach including a comprehensive periodontal examination by
a dentist, we used IgG antibody titers against periodontal
pathogens as a surrogate marker. The validity of antibodies
related to periodontitis in the management of periodontitis has
been confirmed [15,20]. Serum pathogen-specific antibody levels
reflect amounts of periodontal bacteria, and they are useful to
assess the effects of periodontitis treatment [31,32].
Because periodontitis frequently occurs in patients with COPD
[13], we assumed that such patients could be chronically exposed
to periodontitis-related pathogens. Furthermore, P. gingivalis is the
most frequently found pathogen in periodontitis [15]. Thus, serum
levels of P. gingivalis-related antibody might reflect the ability to
generate specific immune responses against infection with bacterial
pathogens. This could be supported by the finding that serum c-
globulin levels were higher in High-IgG titer group than in
Normal-IgG titer group. As bacterial infection is a major cause of
COPD exacerbations [33], we speculated that an insufficient
humoral immune response against bacteria in patients whose
antibody titer against P. gingivalis was normal would be related to
an increase in exacerbation frequency.
Our subanalysis of 27 cytokines using the multiplex bead-based
immunoassay in 62 patients with COPD found higher serum levels
of IL-4 and IL-7 in Normal-IgG titer group than High-IgG titer
group (Table S1 and S2). Serum IL-4 level was measured by
multiple testing in this study. The differences in the cytokine
concentrations might be too small to attach a biological
significance. However, some studies suggested that slight differ-
ence in the IL-4 concentration exerted biological difference
[34,35]. We should be prudent to interpret these results.
The fact that higher serum levels of IL-4 and IL-7 in Normal-
IgG titer group than High-IgG titer group seems to be
contradictory to the fact that IL-4 functions as a B cell growth
factor [36] and IL-7 simulates the proliferation of lymphoid
progenitors [37]. However, we speculated that lower IgG could be
a result from insufficient IgG production in spite of the intense
producing stimuli such as IL-4 and IL-7 in some way that we could
not identify in this research, and impaired negative feedback
system on cytokine production might cause the higher level of IL-4
and IL-7. Another possible explanation is that Th2 cytokine
suppression might influence our results. Papi A et al reported that
airway eosinophil counts were increased during COPD exacerba-
tions associated with virus detection [38] and some studies showed
that virus infection lead to increase of IL-4 and made Th1/2
balance skew toward Th2 cytokines [39]. As a whole, it is possible
that higher IgG titer and lower IL-4 might lead to systemic
Table 3. Inflammatory markers in blood and use of COPD medication in patients between patients with normal and higher IgG






c-globulin, g/dL 1.04 (0.94–1.18) 1.20 (1.05–1.42) 0.0007
C-reactive protein, mg/L 0.82 (0.30–1.86) 0.94 0.36–1.71) 0.66
Use of COPD medications, n(%)
Inhaled corticosteroid 23 (52.3) 15 (30.6) 0.038
Tiotropium 20 (45.5) 17 (34.7) 0.40
Long-acting b2 agonist 15 (34.1) 18 (36.7) 0.83
Salmeterol/fluticasone combination 0 (0) 0 (0) 1.00
High-IgG titer group includes subjects whose titers against Porphyromonas gingivalis (PgFDC381 and/or PgSu63) are above mean+2SD of healthy subsets [20].
Data area expressed as medians (25th–75th percentiles).
doi:10.1371/journal.pone.0040570.t003
Figure 1. Frequency of exacerbations of patients with COPD
and elevated serum IgG antibody titer against Porphyromonas
gingivalis. Annual frequency of exacerbation is lower in patients with
higher IgG titer than with normal IgG titer (1.2 vs. 0.8/year, p = 0.045).
doi:10.1371/journal.pone.0040570.g001
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suppression of Th2 immune programming resulting in the fewer
exacerbation frequencies. However, the differences in these
cytokines in this study were not so prominent and it is difficult
to conclude definitely. Further studies are needed to clarify these
speculations.
We previously showed that abnormal swallowing reflexes are
associated with frequent exacerbations [7]. In the present study,
we examined swallowing reflexes in 56 patients and separately
evaluated the relationship between P. gingivalis-related antibody
titers and exacerbation frequency in groups with normal and
impaired swallowing reflexes. Table S4 shows that being normal-
IgG titers for P. gingivalis-related antibody tended to increase
exacerbation frequency in both groups. Although drawing a
conclusive interpretation from the small sample cohort in the
present study is difficult, we believe that the absence of P. gingivalis-
related antibody contributes to exacerbation frequency regardless
of the status of the swallowing reflex.
To evaluate the relationship between P. gingivalis-related
antibody titers and airway inflammation, we induced sputum in
46 patients by having them inhale 3% hypertonic saline using an
ultrasonic nebuliser (MU-32, Azwell Inc., Osaka, Japan). Table S5
shows that the total cell counts, profiles of inflammatory cells and
inflammatory cytokines (IL-8 and TNF-a) in the supernatants did
not differ between Normal-IgG titer group and High-IgG titer
group. This finding supports the notion that antibody positivity
reflects chronic low-level exposure to periodontitis-related patho-
gens rather than acute exaggerated airway inflammation induced
by periodontitis-related pathogens.
This study has some limitations. Firstly, we could not find the
significant correlation between periodontitis-related antibody titers
and exacerbation frequency. (p = 0.1128, Figure S1). We specu-
lated that the antibody titers might be determined by both the
severity of the infection and the host reactivity, and COPD
exacerbations were affected by various factors such as host defense
mechanisms and the intensity of external insults, resulting in the
difficulty for detecting the association between antibody titer and
exacerbation frequency.
Secondly, since a dentist did not perform a comprehensive
periodontal examination, we could not precisely diagnose
periodontitis. However, the validity of the periodontitis-related
antibody in the management of periodontitis has been confirmed
[15,20]. We thus believe that patients with Pg FDC381 or Pg SU63
antibody had periodontitis, and that periodontitis itself might not
be associated with exacerbation occurrence.
Thirdly, since oral pathogens were not quantitatively cultured,
the extent of exposure to periodontal pathogens could not be
determined. For example, peptostreptococcus spp. and bacteroides spp.
colonized in the oral cavity and causes airway infection. In
addition to that, other bacteria that can colonize in the oral cavity
or nasopharynx except for periodontal pathogens such as
Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae,
Staphylococcus aureus, or Pseudomonas aeruginosa and Para Haemophilus
influenzae were reported to be cultured from sputum at stable state
COPD patients [40]. Also, Bafadhel et al. revealed that 55% of
exacerbations were associated with bacterial infections and sputum
cultures at exacerbations were associated with such bacteria
[41,42]. But their association was still limited and periodontal
pathogens were not investigated, so further investigations are
needed.
Fourthly, we measured P. gingivalis-related antibody only once
during an exacerbation-free state. Unlike paired examinations of
the antibody titers, we could not discriminate bacterial coloniza-
tion from new acquisition of pathogens. However, infection with
Pg FDC381 and Pg SU63, both of which are common pathogens
in periodontitis [15], mainly results in chronic inflammation of the
periodontium. We thus speculated that levels of P. gingivalis-related
antibody reflect the immune response to chronic infection with this
pathogen.
Fifthly, we did not directly investigate the immunological status
of the hosts, such as the ability to produce antibody, because a
methodology has not yet been established.




(n =49) p value
Exacerbation frequency, per year
Median (25th–75th percentiles) 1 (0–2) 0 (0–1) 0.045
Mean 1.2 0.8
Rate of patients with frequent exacerbations, n (%) 17 (38.6) 7 (14.3) 0.009
High-IgG titer group includes subjects whose titers against Porphyromonas gingivalis (PgFDC381 and/or PgSu63) are above mean+2SD of healthy subsets [20].
Frequent exacerbations’’ are defined as $2 exacerbations per year.
doi:10.1371/journal.pone.0040570.t004
Table 5. Multivariable logistic regression analysis to identify
risk factors for frequent exacerbation.
Variables RR 95%CI p-value
Age, per increase of 1 year 1.00 0.93–1.09 0.90
Smoking index, per increase of 1 pack-year 0.98 0.96–1.00 0.10
Body mass index, per increase of 1 kg/m2 0.89 0.70–1.12 0.34
CRP, per increase of 1 mg/ml 0.99 0.99–1.00 0.70
c-globulin, per increase of 1 g/dL 2.07 0.17–25.1 0.56
ICS, yes/no 2.01 0.57–7.55 0.28
Tiotropium, yes/no 1.53 0.41–5.80 0.52
LABA, yes/no 1.31 0.33–5.20 0.69
%FEV1, per increase of 1% 0.99 0.94–1.02 0.49
Exacerbations in previous year, yes/no 4.43 1.20–19.6 0.025
Normal IgG antibody titer against
Porphyromonas gingivalis., yes/no
5.27 1.30–25.7 0.019
Frequent exacerbation is defined as $2 exacerbations per year.
RR, relative risk; CI, confidence interval; CRP, C-reactive protein; ICS, inhaled
corticosteroid; LABA, long-acting b2 agonist.
doi:10.1371/journal.pone.0040570.t005
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Conclusion
In conclusion, normal-IgG titer for P. gingivalis-related antibody
can be an independent predictor of exacerbation frequency.
Measuring P. gingivalis-related antibody titers might be useful to
identify patients with susceptibility to frequent exacerbations so
that an aggressive strategy can be designed to prevent exacerba-
tion.
Supporting Information
Figure S1 Frequency of exacerbations of patients with
COPD and serum IgG antibody titer against Porphyr-
omonas gingivalis. Annual frequency of exacerbation is not
correlated with Porphyromonas gingivalis-related antibody titers
(p = 0.1128).
(TIF)
Table S1 Patients’ baseline characteristics (n = 62).
(DOC)
Table S2 Comparison of 27 cytokines between patients with
normal and higher IgG titer against Porphyromonas gingivalis:
subanalysis of 62 patients.
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Table S3 Frequency of exacerbations and elevated serum IgG
antibody titer against Porphyromonas gingivalis in dentate patients
group.
(DOC)
Table S4 Frequency of exacerbations and elevated serum IgG
antibody titer against Porphyromonas gingivalis in patients with
normal and abnormal swallowing reflexes: subanalysis of 56
patients.
(DOC)
Table S5 Comparison of inflammatory markers in sputum from
patients with normal and higher IgG titer against Porphyromonas
gingivalis: subanalysis of 46 patients.
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